VIVUS Announces November Investor Conference Schedule

VIVUS Announces November Investor Conference Schedule

MOUNTAIN VIEW, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS) today announced that VIVUS management will participate at four
investor conferences during the month of November.

The conference schedule is as follows:

Brean Capital Life Sciences Summit
Wednesday, November 7, 2012
New York, NY
Presenter: Tim Morris; Chief Financial Officer

Bank of America Merrill Lynch 2012 One-on-One Conference
Thursday, November 8, 2012
Los Angeles, CA
Presenter: Peter Tam, President

Lazard Capital Markets 9^th Annual Healthcare Conference
Tuesday, November 13, 2012
2:30 p.m. EST
New York, NY
Presenter: Leland Wilson, Chief Executive Officer

Credit Suisse 2012 Healthcare Conference
Thursday, November 15, 2012
10:30 a.m. MST
Phoenix, AZ
Presenter: Tim Morris; Chief Financial Officer

A live webcast and 30-day archive of the Lazard Capital Markets and Credit
Suisse presentations will be available at


VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health for U.S., Europe and other world markets.
Qsymia is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea.For more information about the company,
please visit

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, our lack of commercial experience
with Qsymia in the U.S.; the timing of initiation and completion of the
clinical studies required as part of the approval of Qsymia by the United
States Food and Drug Administration, or FDA; the response from the FDA to the
data that VIVUS will submit relating to post-approval clinical studies; the
impact of the indicated uses and contraindications contained in the Qsymia
label and the REMS requirements; the impact of distribution of Qsymia through
a certified pharmacy network; whether or not the FDA approves our amendment to
the REMS for Qsymia, which, if approved, would allow dispensing through select
retail pharmacies to increase access while meeting all requirements of the
REMS; that we may be required to provide further analysis of previously
submitted clinical trial data; our appeal of the negative opinion of the
European Medicines Agency's, or EMA, Committee for Medicinal Products for
Human Use, or CHMP, for the Marketing Authorization Application, or MAA, for
Qsymia; our ability to successfully commercialize or establish a marketing
partnership for avanafil, which will be marketed in the U.S. under the name
STENDRA, or the ability of our partners to maintain regulatory approvals to
manufacture and adequately supply our products to meet demand; our history of
losses and variable quarterly results; substantial competition; risks related
to the failure to protect our intellectual property and litigation in which we
may become involved; uncertainties of government or third party payer
reimbursement; our reliance on sole source suppliers; our limited sales and
marketing and manufacturing experience; our reliance on third parties and our
collaborative partners; our failure to continue to develop innovative
investigational drug candidates and drugs; risks related to the failure to
obtain FDA or foreign authority clearances or approvals and noncompliance with
FDA or foreign authority regulations; our ability to demonstrate through
clinical testing the safety and effectiveness of our investigational drug
candidates; the timing of initiation and completion of clinical trials and
submissions to foreign authorities; the volatility and liquidity of the
financial markets; our liquidity and capital resources; and our expected
future revenues, operations and expenditures. As with any pharmaceutical in
development, there are significant risks in the development, the regulatory
approval, and commercialization of new products. There are no guarantees that
the product will receive regulatory approval outside the United States for any
indication or prove to be commercially successful. VIVUS does not undertake an
obligation to update or revise any forward-looking statements. Investors
should read the risk factors set forth in VIVUS' Form 10-K for the year ending
December 31, 2011, and periodic reports filed with the Securities and Exchange

         Timothy E. Morris
         Chief Financial Officer
         Media Relations:
         Ashley Buford
         Investor Relations:
         The Trout Group
         Brian Korb
Press spacebar to pause and continue. Press esc to stop.